Wholesale hemp prices declining despite fractured US supply chains, investment advisor says

By Hank Schultz contact

- Last updated on GMT

Related tags: Food and drug administration

Investment opportunities in the CBD space continue to abound despite the regulatory uncertainties, the director of a Boulder-based fund says.

Patrick Rea, a former editor of Nutrition Business Journal, now directs Canopy, an investment fund directed toward the cannabis space.  Rea spoke with NutraIngredients-USA at the recent Supply Side West trade show in Las Vegas, NV.

CBD—banned, but no pariah

The fraction of cannabis most relevant to the dietary supplement industry is cannabidiol, or CBD. The Food and Drug Administration earlier this year flatly said that CBD is not a legal dietary ingredient, but that hasn’t stopped product developers from nudging around the edges of that envelope. The big reason for that, Rea said, is beyond the current dearth of products (and any self respecting market abhors a vacuum) is that the CBD molecule itself has so many promising properties.

“It has enormous applications. It is an antioxidant, it protects brain cells, there are some studies out from the NIH that shows it destroys cancer cells,”​ Rea said. 

“They are just seriously understudied because the DEA (Drug Enforcement Administration) controls the licenses that are assigned or given to clinicians, academics and researchers.  Let’s not forget that cannabis is still Schedule One drug,”​ he said.

Assuming that FDA’s current ban on CBDs were somehow to be lifted or the drug status of the plant were to change, as many advocates expect, what could legally be said about them?

“I think that everyone will have to come up with new claims,”​ Rea said. “I think a lot of the claims under DSHEA are pretty gutless.  

“But just like the supplement industry today there is a lot of information out there on the plant that people can study. Remember, this is an herb, just like St Johns Wort. It is one of the most efficacious plants that we have found. It just needs to be studied more,”​ he said.

Supply questions

Rea said that the supply end of the picture is still somewhat clouded. DEA has been interdicting shipments of plants and seeds across state lines, so supplies of plant material are confined to within the states where it is legal, something that would have to change for full scale commerce to take place.

“Certainly the way legalization is occurring right now is there are state by state silos. You can’t grow and produce anything in one state where it is legal and take it to another state where it is legal, so there is no interstate commerce. But what we have seen is wholesale prices coming down as more efficient growers get into the market,”​ he said.

Related news

Show more

Related products

show more

The biomimetic approach of Indena

The biomimetic approach of Indena

Indena: the botanical ingredient of Health Food industry | 25-Feb-2019 | Technical / White Paper

In the recent years the turmeric market has become deeply crowded and "noisy". The sometimes too technical approach used by certain brands confuses...

Sabinsa: Committed to Science, Nature, and Health

Sabinsa: Committed to Science, Nature, and Health

SABINSA | 14-Feb-2019 | Technical / White Paper

Since 1988 Sabinsa has amplified the wisdom of the past using modern science, technology, and quality standards. The founder’s belief that sustainable...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars